Mr. Hong Zhao is joining SciClone Pharmaceuticals as its new Chief Executive Officer¬–China Operations. An accomplished industry executive, Mr. Zhao has over 20 years in the pharmaceutical industry and has led the commercial operations, market expansion, and growth of several multi-national companies throughout China.
Mr. Zhao joins SciClone from Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals. As the company’s Executive Vice President, his responsibilities included leading a sizeable sales team and managing multiple business units, and had direct reporting responsibility for medical affairs, market access, marketing and sales operations, training, and personnel development.
Prior to Simcere, he held various senior positions at Novartis China, including Regional Sales Manager, National Sales Director, Vice President, Senior Vice President of Novartis Greater China and General Manager of Novartis Shanghai. Mr. Zhao also served with Xi’an Janssen Pharmaceutical, where he rose quickly from Medical Representative to District Sales Manager. Mr. Zhao holds a Bachelor of Medicine degree from Nanjing Medical College and an Executive Masters of Business Administration degree from China European International Business School (CEIBS). He is fluent in Mandarin and in English.
“Hong Zhao is a skilled executive with proven ability to exceed aggressive performance goals, deliver strong top and bottom-line performance, manage and inspire effective sales organizations, establish productive relationships with industry partners and implement innovative and effective corporate strategies,” said Friedhelm Blobel, Ph.D., SciClone’s Chief Executive Officer. “Throughout his career, he has demonstrated the ability to bring new ways of thinking into his companies, implement effective sales force management strategies, incentives and performance measures, align organizations toward growth and leverage the full potential of individuals and teams. SciClone’s board of directors and management team join me in welcoming Hong to our Company. We look forward to working together to lead SciClone to its next level of performance in China.”
“I believe that SciClone has significant potential to enhance its stature and reputation as a growth-focused mid-size pharmaceutical company with a high quality, differentiated marketed product portfolio, led by ZADAXIN®, one of the most respected brands among patients and physicians in China,” added Mr. Zhao. “I look forward to working with Friedhelm and the talented SciClone team to build a consistently top-performing commercial organization, strengthen our focus on ensuring compliance and integrity throughout our operations and continue to deliver value to all of our stakeholders.”
For more information, visit www.sciclone.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
